Double maintains 1 strategies that include ACLX - Arcellx, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -49.01% | $109.64M | 0.85% |
TAIL | -42.88% | $140.49M | 0.59% |
BTAL | -39.46% | $361.41M | 1.43% |
IVOL | -25.20% | $353.94M | 1.02% |
FTSD | -16.79% | $212.46M | 0.25% |
FXY | -15.62% | $838.61M | 0.4% |
XONE | -15.51% | $603.24M | 0.03% |
XHLF | -14.85% | $1.46B | 0.03% |
SPTS | -12.67% | $5.76B | 0.03% |
UTWO | -12.10% | $387.71M | 0.15% |
IBTG | -11.60% | $1.88B | 0.07% |
VGSH | -11.33% | $22.38B | 0.03% |
SCHO | -11.14% | $10.87B | 0.03% |
LDUR | -11.00% | $849.09M | 0.5% |
IBTH | -9.53% | $1.53B | 0.07% |
BILS | -9.33% | $3.96B | 0.1356% |
GBIL | -9.21% | $6.17B | 0.12% |
IBTI | -8.80% | $995.39M | 0.07% |
CTA | -8.79% | $1.05B | 0.76% |
WEAT | -7.63% | $115.83M | 0.28% |
Yahoo
REDWOOD CITY, Calif., May 14, 2025--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan on
Yahoo
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell […]
Yahoo
Arcellx ( NASDAQ:ACLX ) First Quarter 2025 Results Key Financial Results Revenue: US$8.13m (down 79% from 1Q 2024). Net...
Yahoo
Arcellx (ACLX) delivered earnings and revenue surprises of -34.52% and 55.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
REDWOOD CITY, Calif., May 08, 2025--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025.
SeekingAlpha
Legend Biotech faces a 60% stock drop amid safety, supply issues, and competition for its CAR-T therapy, Carvykti. See here for an analysis of LEGN stock.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 67.43% | $4.85B | 0.35% |
IBB | 62.50% | $5.22B | 0.45% |
GNOM | 60.09% | $40.65M | 0.5% |
PBE | 59.28% | $214.12M | 0.58% |
IWC | 58.44% | $766.88M | 0.6% |
PTH | 58.36% | $96.56M | 0.6% |
IWO | 58.31% | $11.36B | 0.24% |
VTWO | 57.93% | $12.07B | 0.07% |
IWM | 57.92% | $63.95B | 0.19% |
KJUL | 57.47% | $113.35M | 0.79% |
SCHA | 57.06% | $16.91B | 0.04% |
KJAN | 56.45% | $305.13M | 0.79% |
ISCG | 56.33% | $645.00M | 0.06% |
ESML | 56.06% | $1.81B | 0.17% |
GSSC | 56.04% | $538.65M | 0.2% |
NUSC | 56.03% | $1.14B | 0.31% |
SMMD | 55.96% | $1.46B | 0.15% |
FYX | 55.88% | $811.75M | 0.6% |
IWN | 55.79% | $11.10B | 0.24% |
PRFZ | 55.58% | $2.33B | 0.34% |
Current Value
$58.371 Year Return
Current Value
$58.371 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -15.90% | $22.95B | +20.67% | 1.12% |
K | -11.68% | $28.49B | +32.17% | 2.77% |
AQB | -10.69% | $2.96M | -61.58% | 0.00% |
FMTO | -10.63% | $45.74M | -99.96% | 0.00% |
STG | -8.02% | $27.05M | -37.35% | 0.00% |
AIFU | -7.69% | $9.85M | -95.03% | 0.00% |
LITB | -7.03% | $21.28M | -72.45% | 0.00% |
EXC | -6.58% | $43.84B | +12.45% | 3.59% |
CYCN | -6.02% | $9.37M | +2.39% | 0.00% |
PSQH | -5.85% | $89.26M | -49.87% | 0.00% |
FINV | -5.39% | $1.19B | +69.11% | 3.27% |
T | -5.32% | $196.66B | +57.98% | 4.07% |
ZCMD | -5.26% | $32.45M | -11.38% | 0.00% |
PCRX | -4.91% | $1.19B | -18.76% | 0.00% |
BTCT | -4.75% | $25.35M | +93.08% | 0.00% |
MO | -4.20% | $97.80B | +26.35% | 6.94% |
CME | -4.06% | $98.74B | +28.80% | 3.84% |
ED | -4.02% | $36.75B | +5.26% | 3.28% |
HSY | -3.80% | $33.16B | -21.37% | 3.44% |
TEF | -3.42% | $27.20B | +8.80% | 6.44% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KRYS | 57.33% | $3.77B | -20.42% | 0.00% |
DNLI | 57.26% | $2.06B | -30.04% | 0.00% |
RCKT | 56.01% | $724.54M | -71.26% | 0.00% |
XNCR | 55.17% | $583.60M | -63.49% | 0.00% |
KYMR | 54.18% | $1.95B | -15.67% | 0.00% |
RNA | 53.89% | $3.49B | +0.87% | 0.00% |
BEAM | 53.50% | $1.73B | -27.49% | 0.00% |
SYRE | 53.15% | $877.54M | -61.53% | 0.00% |
TBCH | 52.87% | $248.61M | -22.58% | 0.00% |
ROIV | 52.78% | $7.68B | -5.70% | 0.00% |
IPGP | 52.33% | $2.78B | -26.19% | 0.00% |
LGND | 51.94% | $2.00B | +21.70% | 0.00% |
CRSP | 50.97% | $3.14B | -34.78% | 0.00% |
CRNX | 50.39% | $2.92B | -39.88% | 0.00% |
KRC | 49.83% | $3.84B | -6.47% | 6.67% |
RCUS | 49.29% | $907.43M | -50.92% | 0.00% |
IMNM | 49.25% | $696.10M | -44.44% | 0.00% |
RGNX | 48.75% | $433.39M | -46.03% | 0.00% |
RVMD | 48.74% | $7.35B | +1.15% | 0.00% |
IDYA | 48.48% | $1.52B | -58.32% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DADA | 0.22% | $526.11M | +11.54% | 0.00% |
VZ | 0.28% | $183.32B | +8.02% | 6.21% |
PPC | -0.31% | $11.21B | +41.54% | 0.00% |
VHC | -0.31% | $34.69M | +74.89% | 0.00% |
KR | 0.43% | $44.68B | +24.17% | 1.89% |
FE | 0.63% | $24.49B | +5.52% | 4.06% |
BTI | 0.67% | $90.76B | +31.13% | 7.29% |
GFI | 0.95% | $18.61B | +31.67% | 2.75% |
PULM | -0.95% | $23.82M | +239.64% | 0.00% |
UUU | 1.10% | $4.93M | +40.20% | 0.00% |
VSTA | 1.19% | $326.82M | +11.64% | 0.00% |
AEP | -1.21% | $54.28B | +9.80% | 3.61% |
PM | -1.25% | $263.27B | +68.03% | 3.17% |
SRRK | 1.26% | $2.92B | +115.29% | 0.00% |
DOGZ | 1.26% | $231.95M | +120.05% | 0.00% |
SYPR | 1.27% | $37.69M | +21.48% | 0.00% |
LU | 1.40% | $2.45B | -35.82% | 0.00% |
DAO | -1.42% | $276.47M | +139.85% | 0.00% |
PINC | 1.48% | $1.88B | +15.22% | 3.69% |
LTM | 1.51% | $11.01B | -96.75% | 2.75% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILZ | 0.06% | $876.85M | 0.14% |
STXT | -0.09% | $134.15M | 0.49% |
NEAR | 0.11% | $3.26B | 0.25% |
KCCA | 0.27% | $97.18M | 0.87% |
BUXX | 0.28% | $284.43M | 0.25% |
IBTP | -0.34% | $129.44M | 0.07% |
ASHR | -0.34% | $1.95B | 0.65% |
UTEN | -0.38% | $192.72M | 0.15% |
LGOV | -0.44% | $684.47M | 0.67% |
FMHI | -0.46% | $757.44M | 0.7% |
IBTF | 0.54% | $2.12B | 0.07% |
TAXF | 0.60% | $500.81M | 0.29% |
IEF | -0.70% | $34.17B | 0.15% |
CNYA | -0.87% | $221.25M | 0.6% |
GSST | 0.91% | $857.21M | 0.16% |
STIP | 1.24% | $11.88B | 0.03% |
FMB | 1.40% | $1.91B | 0.65% |
VTIP | -1.45% | $14.78B | 0.03% |
IBTO | -1.46% | $330.69M | 0.07% |
GVI | 1.49% | $3.37B | 0.2% |